Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.

Nicola Di Renzo, Maurizio Musso, Rosanna Scimè, Alessandra Cupri, Tommasina Perrone, Clara De Risi, Domenico Pastore, Attilio Guarini, Andrea Mengarelli, Fabio Benedetti, Patrizio Mazza, Saveria Capria, Patrizia Chiusolo, Luca Cupelli, Vincenzo Federico, Valentina Bozzoli, Anna Rita Messa, Rosella Matera, Davide Seripa, Paolo CodegaErminio Bonizzoni, Giorgina Specchia

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is particularly challenging for patients receiving highly emetogenic preparative regimens before autologous stem cell transplantation (ASCT) due to the daily and continuous emetogenic stimulus of the multiple day chemotherapy. While studies have shown effective prevention of CINV during the conditioning phase with NK1 receptor antagonist (NK1RA)-containing regimens, there have been no studies evaluating antiemetic use during chemomobilization prior to ASCT. Methods: This multicenter, open-label, phase IIa study evaluated the efficacy of every-other-day dosing of NEPA administered during chemomobilization in patients with relapsed-refractory aggressive non-Hodgkin’s lymphoma. Eighty-one patients participated. Results: Response rates were 77.8% for complete response (no emesis and no rescue use), 72.8% for complete control (complete response and no more than mild nausea), 86.4% for no emesis, and 82.7% for no rescue use during the overall phase (duration of chemomobilization through 48 h after). NEPA was well tolerated with no treatment-related adverse events reported. Conclusion: NEPA, administered with a simplified every-other-day schedule, show to be very effective in preventing CINV in patients at high risk of CINV undergoing to chemomobilization of hematopoietic stem cells prior to ASCT.

Original languageEnglish
JournalSupportive Care in Cancer
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • ASCT
  • CINV
  • Multiday chemotherapy
  • NEPA
  • Netupitant
  • Palonosetron

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.'. Together they form a unique fingerprint.

Cite this